Sign in

    Davinthra Thillainathan

    Healthcare Equity Analyst at Goldman Sachs

    Davinthra Thillainathan is a Healthcare Equity Analyst at Goldman Sachs, specializing in coverage of major healthcare firms such as CSL Limited, ResMed, Ramsay Health Care, and Sonic Healthcare. With an analyst success rate of 50% and an average return per recommendation of -0.80%, Thillainathan’s calls have included highly profitable ratings like a 4.5% return for CSL. Since joining Goldman Sachs, Thillainathan has provided targeted recommendations and forecasts across Australian and European healthcare stocks and is recognized for contributing to sector insights published by leading financial platforms. Professional credentials and securities licenses are not publicly listed.

    Davinthra Thillainathan's questions to RESMED (RMD) leadership

    Davinthra Thillainathan's questions to RESMED (RMD) leadership • Q4 2025

    Question

    Davinthra Thillainathan of Goldman Sachs questioned the post-acquisition roadmap for Virtuox, including planned investments and the key indicators for measuring returns.

    Answer

    CEO Michael Farrell positioned the Virtuox acquisition as part of a broader strategy to expand the diagnostic funnel, alongside Ectosense and Somnware. He stated the goal is to scale home sleep apnea testing (HSAT) to reduce lab waitlists and bring more patients to therapy, viewing it as a long-term strategic play.

    Ask Fintool Equity Research AI

    Davinthra Thillainathan's questions to RESMED (RMD) leadership • Q4 2025

    Question

    Davinthra Thillainathan of Goldman Sachs questioned the strategic roadmap for the newly acquired Virtuox business, including future investment areas and the key indicators for measuring its success.

    Answer

    CEO & Chairman Michael Farrell positioned the Virtuox acquisition as part of a broader portfolio strategy, alongside Ectosense and Somnware, aimed at improving the patient diagnostic funnel. He explained the goal is to scale home sleep apnea testing (HSAT) to reduce waitlists and free up sleep labs for more complex cases, ultimately driving more patients to therapy. He emphasized it is a long-term strategic play.

    Ask Fintool Equity Research AI